Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03628677
Title A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Arcus Biosciences, Inc.
Indications

head and neck squamous cell carcinoma

renal cell carcinoma

breast cancer

Merkel cell carcinoma

urinary bladder cancer

colorectal cancer

ovarian cancer

endometrial cancer

lung non-small cell carcinoma

melanoma

gastroesophageal cancer

Therapies

AB154

AB154 + Zimberelimab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
The Angeles Clinic and Research Institute Los Angeles California 90025 United States Details
Carolina BioOncology Institute Huntersville North Carolina 28078 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
START San Antonio Texas 78229 United States Details
Medical Oncology Associates, PS (dba Summit Cancer Centers) Spokane Washington 99208 United States Details
Albury, Australia Albury New South Wales 2640 Australia Details
Principal Investigator Camperdown New South Wales 2050 Australia Details
The Kinghorn Cancer Centre Darlinghurst New South Wales 2010 Australia Details
Scientia Clinical Research Randwick New South Wales 2031 Australia Details
Principal Investigator Tweed Heads New South Wales 2480 Australia Details
Principal Investigator South Brisbane Queensland 4101 Australia Details
Olivia Newton-John Cancer Research Institute Heidelberg Victoria 3084 Australia Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field